J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.
Read the full article on the original site.
Read Full Article